Debevoise Advises Guggenheim as Financial Advisor to Gilead in Its $4.3 Billion Acquisition of CymaBay

12 February 2024

Debevoise & Plimpton LLP is advising Guggenheim Securities LLC as financial advisor to Gilead Sciences Inc. in its $4.3 billion acquisition of biopharmaceutical company CymaBay Therapeutics Inc. For more information, please see the company’s press release.

The Debevoise team is led by M&A partner Andrew Bab and includes associate Charlotte Walkovik.